All
Potential effect of temperature changes on anti-VEGF drugs
PulseSight Therapeutics submits Clinical Trial Authorization for phase I trial of PST-611
The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy
Outlook Therapeutics completes analysis of 12-week safety and efficacy results of NORSE EIGHT
The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics License Application in the first quarter of 2025.
Macrophomina phaseolina: An emerging ocular infection in humans
They report a case of endophthalmitis and undertook a literature review to identify previous infections with this pathogen.
Cost-effectiveness of AI pediatric eye screening
Cost among other factors may deter patients from screening, especially in rural and low-resource settings.
Inflammasome Therapeutics announces positive topline 3-month data of K8 implant in patients with GA
In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.
RhyGaze secures Series A financing of $86 million to further novel gene therapy
The funding will support activities like formal pharmacology and toxicology testing.
EyePoint Pharmaceuticals provides company updates, 2025 milestones for Duravyu
The company's lead product candidate Duravyu (vorolanib intravitreal insert), f/k/a EYP-1901, is anticipating topline data from several clinical trials in 2026.
InflammX Therapeutics enters into option agreement with Bausch + Lomb
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration.
Positive association between the dietary inflammatory index and non-refractive visual impairment in US patients
Ashvattha Therapeutics secures $50M in financing to advance clinical trials
The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME
Samsara Vision announces positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery
The retrospective SING IMT study included 35 patients (55 years or older) with late-stage age-related macular degeneration (AMD).
Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)
Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).
4DMT releases positive topline interim data from Part 1 of the SPECTRA clinical trial
The objective of this trial was to evaluate safety and tolerability and identify dose level for further evaluation.
Bausch + Lomb acquires Whitecap Biosciences
Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.
Positive 2-year safety and efficacy update for Phase 1/2 OCU400 for the treatment of RP
OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.
City Therapeutics and Bausch + Lomb collaborate on GA treatment candidate
City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.
New research links retinal imaging and deep learning to improved schizophrenia detection
Topline results from phase 2b clinical trial of UBX1325 for DME expected in Q1 2025
This phase 2b study (ASPIRE) is currently underway.
A connection between sleep apnea and AMD
The FDA accepts revised supplemental New Drug Application for IZERVAY
The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.
Companies appoint new leadership across the industry
Several pharmaceutical companies have announced new appointments of executives and board members as they prepare for growth in 2025.
Aviceda Therapeutics completes $207.5 million Series C financing in support of AVD-104 for geographic atrophy treatment
The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.
FDA grants rare pediatric disease designation for retinitis pigmentosa gene therapy candidate VG901 from ViGeneron
ViGeneron also received approval for dose escalation in the ongoing phase 1b clinical trial.
Regeneron acquires UK biotech company Oxular, broadening retina portfolio
In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema
Oculis releases positive topline results from phase 2 ACUITY trial evaluating OSC-05 in acute optic neuritis
The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).
Korea Institute of Science and Technology (KIST) enters technology transfer agreement with Huons BioPharma
The collaboration between KIST and Huons BioPharma will span 14 months.
OCT and OCTA findings in fibromyalgia
Topcon Healthcare appoints Jacques Gilbert to Chief Strategy and Business Development Officer
Most recently, Jacques served as Vice President of Healthcare Strategy, Partnerships & M&A at Microsoft.
European Medicines Agency will assess semaglutide for link to NAION
The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition
